Incyte Corporation

INCYintermediary

Incyte is a specialty biopharmaceutical company focused on oncology and inflammation, anchored by the blockbuster JAK inhibitor Jakafi and expanding into dermatology with Opzelura.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($3.9B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Jakafi (55%)

Opzelura (18%)

Other Products (12%)

Royalties & Milestones (15%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Jakafi (ruxolitinib)55%

First-in-class JAK1/JAK2 inhibitor for myelofibrosis and GVHD

Opzelura (ruxolitinib cream)18%

Topical JAK inhibitor for atopic dermatitis and vitiligo

Monjuvi (tafasitamab)8%

Anti-CD19 antibody for diffuse large B-cell lymphoma

Royalties & Pipeline19%

Royalties from Pemazyre, Zynyz, and pipeline collaboration payments

Lieferkettenbeziehungen

Wettbewerber

Eli Lilly and Company

JAK inhibitor market (Olumiant)

Auswirkung: Medium — competing JAK inhibitors

AbbVie Inc.

JAK inhibitor market (Rinvoq)

Auswirkung: High — Rinvoq is major JAK competitor

Wichtige Kunden

Walgreens Boots Alliance

Specialty pharmacy distribution

Auswirkung: Medium — pharmacy channel

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Incyte Corporation.

Unternehmensinformationen

Hauptsitz

Wilmington, Delaware, USA

Gegründet

1991

Mitarbeiter

2,300+

Website

incyte.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten